Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs

By Di Marzo Vincenzo   Bisogno Tiziana   Petrocellis Luciano De  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 3, 2001-06 ,pp. : 349-362

Informa Healthcare

Access to resources Recommend Favorite

Natural Endocannabinoid Derivatives as Templates for the Development of FAAH Inhibitors

By  

Letters in Drug Design & Discovery, Vol. 2, Iss. 5, 2005-08 ,pp. : 372-376

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery and Development of Endocannabinoid-Hydrolyzing Enzyme Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 8, 2010-06 ,pp. : 828-858

Bentham Science Publishers

Access to resources Recommend Favorite

The Molecular Basis for the Mode of Action of Bicyclomycin

By  

Current Drug Targets - Infectious Disorders, Vol. 5, Iss. 3, 2005-09 ,pp. : 273-295

Bentham Science Publishers

Access to resources Recommend Favorite

Carbonic anhydrase inhibitors. Part 37. Novel classes of isozyme I and II inhibitors and their mechanism of action. Kinetic and spectroscopic investigations on native and cobalt-substituted enzymes

By Briganti F.   Pierattelli R.   Scozzafava A.   Supuran C.  

European Journal of Medicinal Chemistry, Vol. 31, Iss. 12, 1996-01 ,pp. : 1001-1010

Elsevier

Access to resources Recommend Favorite